EXSCIENTIA PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.32 USD | +1.65% |
|
-9.15% | -32.61% |
| Mar. 21 | Exscientia Files $300 Million Mixed Shelf | MT |
| Mar. 21 | Transcript : Exscientia plc, 2023 Earnings Call, Mar 21, 2024 |
| Sales 2024 * | 57.86M 72.07M | Sales 2025 * | 49.11M 61.16M | Capitalization | 431M 537M |
|---|---|---|---|---|---|
| Net income 2024 * | -186M -232M | Net income 2025 * | -192M -239M | EV / Sales 2024 * | 2.82 x |
| Net cash position 2024 * | 268M 334M | Net cash position 2025 * | 252M 314M | EV / Sales 2025 * | 3.64 x |
| P/E ratio 2024 * |
-2.46
x | P/E ratio 2025 * |
-2.55
x | Employees | 483 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 36.07% |
More Fundamentals
* Assessed data
More news
Latest transcript on Exscientia plc
More recommendations
More news
| 1 day | +1.65% | ||
| 1 week | -9.15% | ||
| Current month | -24.48% | ||
| 1 month | -32.29% | ||
| 3 months | -30.55% | ||
| 6 months | -18.80% | ||
| Current year | -32.61% |
1 week
4.17
4.93
1 month
4.176.88
Current year
4.177.91
1 year
4.179.12
3 years
4.0930.38
5 years
4.0930.38
10 years
4.0930.38
| Managers | Title | Age | Since |
|---|---|---|---|
David Hallett
CEO | Chief Executive Officer | 54 | 20-01-20 |
Ben Taylor
DFI | Director of Finance/CFO | 46 | 20-11-17 |
| Chief Tech/Sci/R&D Officer | - | 22-04-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Mario Polywka
BRD | Director/Board Member | 61 | 17-09-27 |
Elizabeth Crain
CHM | Chairman | 59 | 21-02-08 |
Ben Taylor
DFI | Director of Finance/CFO | 46 | 20-11-17 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.04% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-17 | 4.32 | +1.65% | 430,377 |
| 24-04-16 | 4.25 | -2.52% | 570,147 |
| 24-04-15 | 4.36 | -6.34% | 552,796 |
| 24-04-12 | 4.655 | -5.19% | 340,699 |
| 24-04-11 | 4.91 | +3.26% | 407,504 |
Delayed Quote Nasdaq, April 17, 2024 at 04:00 pm EDT
More quotes
Exscientia PLC is a United Kingdom-based intelligence-driven (AI) precision medicine company. The Company is focused on discovering, designing and developing the possible drugs. The Company has developed the functional precision oncology platform to guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Its internal pipeline is focused on leveraging its precision medicine platform in oncology, while its partnered pipeline broadens its approach to other therapeutic areas. Its patient-first AI includes Precision Target, Precision Design, Precision Experiment, Precision Medicine, Presentations and Publications. Its Precision Target combines genetic data and global literature in machine learning models to anticipate and confirm disease-target associations. Its advanced biophysical and x-ray techniques provide the ideal experimental underpinnings for AI-design.
Calendar
2024-05-21
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
3.418
GBP
Average target price
6.828
GBP
Spread / Average Target
+99.79%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -32.61% | 536M | |
| -1.78% | 41.71B | |
| +47.70% | 41.56B | |
| +4.01% | 39.74B | |
| -15.14% | 25.61B | |
| +3.16% | 24.26B | |
| -24.08% | 18.55B | |
| -2.67% | 11.93B | |
| +24.76% | 11.93B | |
| +7.01% | 10.91B |
- Stock Market
- Equities
- EXAI Stock
